Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
The tumor embolization devices market has witnessed significant growth recently, driven by advancements in cancer treatment and increasing prevalence of tumors worldwide. With continued innovations and rising healthcare investments, this sector is set to expand further, offering promising opportunities for improved, minimally invasive cancer therapies. Let’s explore the current state, key growth factors, market segmentation, recent technological progress, leading companies, and regional dynamics shaping this market.
Strong Growth in Tumor Embolization Devices Market Size and Forecast
The tumor embolization devices market has seen robust expansion over recent years. It is projected to grow from $1587.48 billion in 2025 to $1732.02 billion in 2026, at a compound annual growth rate (CAGR) of 9.1%. This growth reflects increased adoption of interventional oncology procedures, a rising number of solid tumor cases, and enhanced catheter technologies. Looking ahead, the market is expected to reach $2464.52 billion by 2030, growing at a CAGR of 9.2%. Factors supporting this forecast include greater investments in interventional oncology, growing demand for combination therapies, advancements in targeted drug delivery, and a stronger emphasis on organ-preserving treatments. Additionally, the integration of imaging-guided interventions and the rise of minimally invasive oncology methods are key trends fueling market expansion.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3352&type=smp
The Rising Burden of Cancer as a Market Driver
One of the primary factors propelling the tumor embolization devices market is the increasing global incidence of cancer. Cancer, characterized by uncontrolled cell growth with potential to spread throughout the body, is becoming more common, especially among aging populations. Older individuals face a higher risk due to accumulated genetic changes and prolonged exposure to carcinogens. Tumor embolization devices provide targeted treatments by blocking the blood supply to tumors, slowing their progression and improving patient outcomes. For example, in 2023, the American Cancer Society reported 1,958,310 new cancer cases diagnosed in the United States, surpassing the 1,918,030 cases recorded in 2022. This upward trend in cancer diagnoses worldwide is expected to drive demand for embolization devices in the years ahead.
Increasing Healthcare Spending as a Growth Catalyst
Rising healthcare expenditures are playing a crucial role in advancing the tumor embolization devices market. Healthcare spending covers various services, including preventive care, emergency assistance, and nutrition programs, all of which contribute to better health infrastructure and product development. For instance, a May 2023 report from the UK’s Office for National Statistics indicated that healthcare spending in the UK grew by 5.6% between 2022 and 2023, reaching approximately $317.63 billion (£292 billion). This increased financial commitment to healthcare enables the development and wider adoption of tumor embolization technologies, thereby supporting market growth.
Access The Complete Tumor Embolization Devices Market Report:
https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report
How the Tumor Embolization Devices Market is Organized by Key Categories
The tumor embolization devices market is segmented across several important categories:
1) By Type: Radioembolic Agents and Non-radioactive Embolic Agents
2) By Application: Cancer Tumors and Noncancerous Tumors
3) By End User: Hospitals, Cancer Treatment Centers, Intensive Care Units, and Surgical Centers
Further breakdown includes:
– Radioembolic Agents such as Yttrium-90 (Y-90) Microspheres and Holmium-166 Microspheres
– Non-radioactive Embolic Agents including Drug-Eluting Beads (DEBs), Polyvinyl Alcohol (PVA) Microspheres, Gelatin Sponges, and Liquid Embolic Agents like Onyx and glue-based products
This structured segmentation helps pinpoint specific areas of growth and innovation within the market.
Innovations and Technological Advances Driving Market Transformation
Leading companies in this market are focusing heavily on developing novel therapies and devices to enhance treatment effectiveness. One notable example is Eye90 microspheres, a Y90 radioembolization product designed to treat liver tumors, particularly hepatocellular carcinoma. In May 2023, ABK Biomedical, a Canadian medical device company, received FDA approval to begin a multicenter pivotal trial for Eye90 microspheres. This technology features a proprietary manufacturing process that produces microspheres with uniform size and high radioactivity concentration, enabling targeted radiation delivery to tumors while minimizing damage to healthy tissues. Such innovations are reshaping treatment options and expanding the utility of tumor embolization devices.
Leading Players Shaping the Tumor Embolization Devices Market
The competitive landscape of the tumor embolization devices market is dominated by several prominent companies, including Boston Scientific Corporation, Medtronic plc, Terumo Corporation, Sirtex Medical Limited, Merit Medical Systems Inc., Cook Medical LLC, AngioDynamics Inc., Johnson & Johnson, Penumbra Inc., Teleflex Incorporated, Kaneka Corporation, Guerbet, BTI Biotechnology Institute S.L., BTG International, Avinger Inc., Shape Memory Medical Inc., Delcath Systems Inc., Endoshape Inc., InSitu Technologies Inc., Surefire Medical Inc., and Varian Medical Systems Inc. These firms are continuously investing in research and development to maintain market leadership.
Regional Insights Highlighting Market Leaders and Growth Areas
In 2025, North America held the largest share in the tumor embolization devices market, reflecting the region’s advanced healthcare infrastructure and high adoption rates of interventional oncology techniques. Asia-Pacific followed as the second-largest market, benefiting from expanding healthcare access and growing cancer prevalence. The report also covers other key regions, including South East Asia, Western Europe, Eastern Europe, South America, the Middle East, and Africa, providing a comprehensive view of the global market landscape.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model